(Total Views: 215)
Posted On: 12/23/2020 3:06:07 PM
Post# of 281
NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Integrates Data, AI to Pave Path for Better Health Outcomes
Predictive Oncology (NASDAQ: POAI), a knowledge-driven precision medicine company focused on applying data and artificial intelligence (“AI”) to personalized medicine and drug discovery, is positioned to play a critical role in the precision oncology industry. The company integrates AI technology with oncologists’ clinical decision-making processes, paving the way for improved health outcomes. A recent article discussing this reads, “POAI is focused on the use of data and artificial intelligence to develop personalized cancer therapies through its trove of valuable assets, including a database of clinically validated historical and outcome data from patient tumors, an in-house Clinical Laboratory Improvement Amendments (‘CLIA’)-certified lab, a ‘smart’ patient-derived tumor profiling platform, an in-house bioinformatics artificial intelligence platform, and a proprietary approach to growing tumors in the lab to rapidly develop patient-specific treatment options.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Predictive Oncology (NASDAQ: POAI), a knowledge-driven precision medicine company focused on applying data and artificial intelligence (“AI”) to personalized medicine and drug discovery, is positioned to play a critical role in the precision oncology industry. The company integrates AI technology with oncologists’ clinical decision-making processes, paving the way for improved health outcomes. A recent article discussing this reads, “POAI is focused on the use of data and artificial intelligence to develop personalized cancer therapies through its trove of valuable assets, including a database of clinically validated historical and outcome data from patient tumors, an in-house Clinical Laboratory Improvement Amendments (‘CLIA’)-certified lab, a ‘smart’ patient-derived tumor profiling platform, an in-house bioinformatics artificial intelligence platform, and a proprietary approach to growing tumors in the lab to rapidly develop patient-specific treatment options.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
